A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated

• Main Authors: Jinyang Li (Author), Jiasheng Lu (Author), Haiyan Guo (Author), Jianfen Zhou (Author), Songli Wang (Author), Kuan Jiang (Author), Zhilan Chai (Author), Shengyu Yao (Author), Xiaoyi Wang (Author), Linwei Lu (Author), Cao Xie (Author), Yi Chen (Author), Weiyue Lu (Author)
• Format: Book
• Published: Elsevier, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

AL3810, a molecular dual inhibitor of the vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), has earned the permission of phase II clinical trial for tumor treatment by China FDA. As a reversible ATP-competitive inhibitor, AL3810 targets ATP-binding sit...